PTC Therapeutics (PTCT) Reports Q1 Loss Per Share of $1.15

PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.15), may not compare to the analyst estimate of ($1.20). Revenue for the quarter came in at $7.48 million versus the consensus estimate of $2.97 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Surf Air Mobility names Palantir veteran as president of SurfOS
• B. Riley previews Semi Cap Equipment sector ahead of Semicon West